{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal MSC-AFP",
            "NStudiesAvail": 430108,
            "NStudiesFound": 6,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 6,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Michael C Stephens",
                              "William Faubion"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary endpoint of this study is to determine the safety of using adipose derived, autologous mesenchymal stromal cells (MSC) bound to the Gore Bio-A Fistula Plug for treatment of refractory CD perianal fistulae."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of Subjects with any Adverse Events that are related to study drug"
                        ],
                        "NCTId": [
                              "NCT03014219"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "Michael C Stephens"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Participants will have a health assessment and blood work done at each study visit to monitor for adverse events."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with treatment-related adverse events (safety and toxicity)"
                        ],
                        "NCTId": [
                              "NCT03449069"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Eric J Dozois, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Participants will have a health assessment and blood work measured at each study visit to monitor for adverse events, such as worsening of the cryptoglandular fistulizing disease, abnormal laboratory values, or significant abnormalities in physical examination. The Outcome Measure will be the number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with treatment-related adverse events (safety and toxicity)."
                        ],
                        "NCTId": [
                              "NCT02589119"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [
                              "William A Faubion, M.D.",
                              "Eric J Dozois, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 10, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Participants will have a health assessment and blood work measured at each study visit to monitor for adverse events, such as worsening of the perinal fistulizing disease, abnormal laboratory values, or significant abnormalities in physical examination. The Outcome Measure will be the number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with treatment-related adverse events (safety and toxicity)."
                        ],
                        "NCTId": [
                              "NCT03209700"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [
                              "Amy L Lightner"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 20, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Primary Outcome Measure:\n\n1.Number of participants with treatment-related adverse events (safety and toxicity).\n\nParticipants will have a health assessment and blood work measured at each study visit to monitor for adverse events, such as worsening of the perinal fistulizing disease, abnormal laboratory values, or significant abnormalities in physical examination. The Outcome Measure will be the number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with treatment-related adverse events (safety and toxicity)."
                        ],
                        "NCTId": [
                              "NCT03220243"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [
                              "William Faubion, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary endpoint of this study is to determine the safety and feasibility of using adipose derived, autologous mesenchymal stromal cells (MSC) bound to the Gore\u00ae Bio-A\u00ae Fistula Plug for treatment of refractory CD perianal fistulae."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To determine the safety and toxicity of using autologous MSC coated fistula plug in patients with fistulizing Crohn's Disease."
                        ],
                        "NCTId": [
                              "NCT01915927"
                        ]
                  }
            ]
      }
}